Efficacy of tamoxifen following anastrozole ('Arimidex') compared with anastrozole following tamoxifen as first-line treatment for advanced breast cancer in postmenopausal women.
about
Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal womenAromatase inhibitors for treatment of advanced breast cancer in postmenopausal womenOptimal management of hormone receptor positive metastatic breast cancer in 2016Randomized controlled trial of toremifene 120 mg compared with exemestane 25 mg after prior treatment with a non-steroidal aromatase inhibitor in postmenopausal women with hormone receptor-positive metastatic breast cancerChanges in endocrine therapy: anastrozole and advanced breast cancer in postmenopausal women.High-dose toremifene as first-line treatment of metastatic breast cancer resistant to adjuvant aromatase inhibitor: A multicenter phase II studyArzoxifene: the development and clinical outcome of an ideal SERM.Second-line treatment of postmenopausal women with advanced breast carcinoma.Aromatase inhibitors in post-menopausal metastatic breast carcinoma.Progression of endocrine therapies for breast cancer: where are we headed?Neoadjuvant tamoxifen synchronizes ERα binding and gene expression profiles related to outcome and proliferation.Targeting the mammalian target of rapamycin pathway with everolimus: implications for the management of metastatic breast cancer.Clinical benefit of sequential use of endocrine therapies for metastatic breast cancer.Challenges in the management of advanced, ER-positive, HER2-negative breast cancer.Outcomes of fulvestrant therapy among japanese women with advanced breast cancer: a retrospective multicenter cohort study (JBCRG-C06; Safari).Endocrine Therapy in the Current Management of Postmenopausal Estrogen Receptor-Positive Metastatic Breast Cancer.Fulvestrant 500 mg in postmenopausal patients with metastatic breast cancer: the initial clinical experience.Serial immunological parameters in a phase II trial of exemestane and low-dose oral cyclophosphamide in advanced hormone receptor-positive breast cancer.Androgen metabolite-dependent growth of hormone receptor-positive breast cancer as a possible aromatase inhibitor-resistance mechanism.Hormone receptor-positive, HER2-negative metastatic breast cancer: redrawing the lines.
P2860
Q24239985-37A4F96C-361C-46DA-A2A4-DC237D16F5C8Q24246391-0B3C283A-E66D-4EAF-89D6-6A4640A1B295Q26777683-AF878C6C-0FD1-4CE8-9B19-AA49FD336EECQ34725685-4A603AF4-2341-4ABB-8965-38A123797064Q35990530-8FA75288-EF1E-4AA7-BF47-3DA963A113E0Q35995140-BCEA5F13-9F32-47E9-8856-E1FA7785239CQ36407322-78300F0F-8C2D-487F-B7EC-030C47F8DACEQ36448699-4F2118C3-EAD8-4E36-A80D-D9AF16407A0EQ36861597-4B792540-4EA6-4B7B-9A7F-F3D7FC721CE3Q37004695-2008A6FE-D9D9-4B47-9C20-27B8B20E6DFBQ37376167-258AE15F-8EB5-434B-897E-CFF5EBFB0743Q38223222-45D931E9-91A5-468B-A9B6-4BE82E0A7F15Q38352305-E99031C5-8E5C-40F4-ACB1-344ABB6CF594Q38502890-3AF00E54-7C84-4104-9578-2EAA38D35B91Q38880515-2FF939DE-3B0A-4475-B742-C63122F80F0AQ39185424-2C5225CA-3E86-4578-ABD7-E642476A6B0DQ44107109-5AA3E988-DFDA-4361-B494-840898160BA6Q48328578-78C25D31-3BD4-4265-BAE0-4D9178D9B9B1Q50478764-1790365E-58C4-4B53-865A-4EB9FDCE196AQ55423791-A2FFECB4-1551-4FB7-AE2E-2426B36F8FB2
P2860
Efficacy of tamoxifen following anastrozole ('Arimidex') compared with anastrozole following tamoxifen as first-line treatment for advanced breast cancer in postmenopausal women.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh-hant
name
Efficacy of tamoxifen followin ...... ancer in postmenopausal women.
@en
Efficacy of tamoxifen following anastrozole
@nl
type
label
Efficacy of tamoxifen followin ...... ancer in postmenopausal women.
@en
Efficacy of tamoxifen following anastrozole
@nl
prefLabel
Efficacy of tamoxifen followin ...... ancer in postmenopausal women.
@en
Efficacy of tamoxifen following anastrozole
@nl
P2093
P1476
Efficacy of tamoxifen followin ...... ancer in postmenopausal women.
@en
P2093
Arimidex Study Group
B Thürlimann
J Bonneterre
J F R Robertson
J M Nabholtz
P304
P356
10.1016/S0959-8049(03)00602-6
P577
2003-11-01T00:00:00Z